Physician profile
Michelle Smith
NPI 1871567578
$2,566.87
in general payments reported to CMS, 2019-2025
29 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $153 · 2021: $81.20 · 2022: $429 · 2023: $428 · 2024: $351 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.76 |
| Education | $265.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $474.36 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $320.78 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $263.69 | 2021-2025 | |
| Pfizer INC. | $223.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $192.87 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $160.30 | 2021-2025 | Adbry, Anzupgo |
| Encore Dermatology INC. | $125.54 | 2019-2020 | |
| Lilly USA, LLC | $118.12 | 2022-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $88.43 | 2019-2025 | Nemluvio |
| Amgen INC. | $63.71 | 2019-2025 | Otezla, Otezla |
| Epi Health, LLC | $55.24 | 2019 | |
| Genentech USA, INC. | $51.60 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $46.03 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.39 | 2023 | Spevigo, Cyltezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $33.38 | 2025 | |
| Promius Pharma LLC | $32.69 | 2019 | |
| Ascendis Pharma Endocrinology INC | $28.03 | 2025 | Yorvipath |
| Ucb, INC. | $26.65 | 2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $25.99 | 2019 | |
| Krystal Biotech INC | $24.84 | 2024 | Vyjuvek |
| Celgene Corporation | $24.00 | 2019 | |
| Journey Medical Corporation | $21.44 | 2019 | |
| Cipher Pharmaceuticals US LLC | $20.05 | 2025 | Spinosad, Natroba |
| Mylan Pharmaceuticals INC. | $18.72 | 2019 | |
| Incyte Corporation | $14.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.92 | 2022 | |
| Prugen, INC. Pharmaceuticals | $11.29 | 2019 | |
| Glenmark Therapeutics INC. | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.